Skip to main content

Group Sequential Design Under Non-Proportional Hazards: Deming Conference Course, December 6, 2021

References

[1]
Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J. and Group, for the S. S. S. (1997). Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the scandinavian simvastatin survival study (4S). Circulation 96 4211–8.
[2]
Lan, K. K. G. and DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70 659–63.
[3]
Haybittle, J. (1971). Repeated assessment of results in clinical trials of cancer treatment. The British Journal of Radiology 44 793–7.
[4]
Wang, S. K. and Tsiatis, A. A. (1987). Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 193–9.
[5]
Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64 191–9.
[6]
O’Brien, P. C. and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics 549–56.
[7]
Jennison, C. and Turnbull, B. W. (2000). Group sequential methods with applications to clinical trials. Chapman; Hall/CRC, Boca Raton, FL.
[8]
Gandhi, L., Rodrı́guez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England Journal of Medicine 378 2078–92.
[9]
Downs, J. R., Beere, P. A., Whitney, E., Clearfield, M., Weis, S., Rochen, J., Stein, E. A., Shapiro, D. R., Langendorfer, A. and Gotto Jr, A. M. (1997). Design & rationale of the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). The American Journal of Cardiology 80 287–93.
[10]
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto Jr, A. M., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Journal of the American Medical Association 279 1615–22.
[11]
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. New England Journal of Medicine 369 1327–35.
[12]
Lachin, J. M. and Foulkes, M. A. (1986a). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42 507–19.
[13]
Kim, K. and Tsiatis, A. A. (1990). Study duration for clinical trials with survival response and early stopping rule. Biometrics 46 81–92.
[14]
Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68 316–9.
[15]
Maurer, W. and Bretz, F. (2013). Multiple testing in group sequential trials using graphical approaches. Statistics in Biopharmaceutical Research 5 311–20.
[16]
Hwang, I. K., Shih, W. J. and De Cani, J. S. (1990). Group sequential designs using a family of type i error probability spending functions. Statistics in Medicine 9 1439–45.
[17]
White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011). EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. American Heart Journal 162 620–6.
[18]
De Castro, M., Cancho, V. G. and Rodrigues, J. (2010). A hands-on approach for fitting long-term survival models under the GAMLSS framework. Computer Methods and Programs in Biomedicine 97 168–77.
[19]
Zhang, Y. and Shao, Y. (2018). Concordance measure and discriminatory accuracy in transformation cure models. Biostatistics 19 14–26.
[20]
Zeng, D., Yin, G. and Ibrahim, J. G. (2006). Semiparametric transformation models for survival data with a cure fraction. Journal of the American Statistical Association 101 670–84.
[21]
Hellmann, M. D., Ma, J., Garon, E. B., Hui, R., Gandhi, L., Soria, J.-C., Anderson, K. M., Lubiniecki, G. M., Piperdi, B. and Herbst, R. S. (2017). Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and-010.
[22]
Lan, K. K. G. and DeMets, D. L. (1989). Group sequential procedures: Calendar versus information time. Statistics in Medicine 8 1191–8.
[23]
Harrington, D. P. and Fleming, T. R. (1982). A class of rank test procedures for censored survival data. Biometrika 69 553–66.
[24]
Magirr, D. and Burman, C.-F. (2019a). Modestly weighted logrank tests. Statistics in Medicine 38 3782–90.
[25]
Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis. Statistics in Biopharmaceutical Research 12 187–98.
[26]
Roychoudhury, S., Anderson, K. M., Ye, J. and Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with non-proportional hazards: A straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research 1–37.
[27]
Yung, G. and Liu, Y. (2019). Sample size and power for the weighted log-rank test and kaplan-meier based tests with allowance for nonproportional hazards. Biometrics.
[28]
Lachin, J. M. and Foulkes, M. A. (1986b). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 507–19.
[29]
Magirr, D. and Burman, C.-F. (2019b). Modestly weighted logrank tests. Statistics in Medicine 38 3782–90.
[30]
Karrison, T. G. (2016). Versatile tests for comparing survival curves based on weighted log-rank statistics. The Stata Journal 16 678–90.
[31]
Wang, L., Luo, X. and Zheng, C. (2019). A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards. arXiv preprint arXiv:1911.05684.
[32]
Scharfstein, D. O., Tsiatis, A. A. and Robins, J. M. (1997). Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. Journal of the American Statistical Association 92 1342–50.
[33]
Gordon Lan, K. and DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70 659–63.
[34]
Lachin, J. M. (2005). A review of methods for futility stopping based on conditional power. Statistics in Medicine 24 2747–64.